1. Home
  2. RGNT vs TCRX Comparison

RGNT vs TCRX Comparison

Compare RGNT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regentis Biomaterials Ltd. Ordinary Shares

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

HOLD

Current Price

$0.72

Market Cap

14.3M

Sector

Health Care

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

SELL

Current Price

$0.15

Market Cap

11.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RGNT
TCRX
Founded
2004
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.3M
11.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
RGNT
TCRX
Price
$0.72
$0.15
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
★ $1.00
AVG Volume (30 Days)
43.5K
★ 420.2K
Earning Date
09-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 12.28
EPS
★ N/A
N/A
Revenue
N/A
★ $10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 266.65
52 Week Low
$0.81
$0.14
52 Week High
$15.50
$1.47

Technical Indicators

Market Signals
Indicator
RGNT
TCRX
Relative Strength Index (RSI) 21.62 31.39
Support Level N/A N/A
Resistance Level $2.52 $0.21
Average True Range (ATR) 0.15 0.02
MACD -0.03 0.00
Stochastic Oscillator 3.85 8.07

Price Performance

Historical Comparison
RGNT
TCRX

About RGNT Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: